CTI BioPharma Corp. (NASDAQ:CTIC) Given Consensus Recommendation of “Buy” by Analysts

CTI BioPharma Corp. (NASDAQ:CTICGet Rating) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.83.

A number of equities research analysts have issued reports on CTIC shares. Brookline Capital Management boosted their price target on CTI BioPharma from $7.20 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, March 1st. Brookline Capital Acquisition boosted their price objective on CTI BioPharma from $7.20 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, March 1st. Needham & Company LLC boosted their price objective on CTI BioPharma from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 2nd. JMP Securities boosted their price objective on CTI BioPharma from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com initiated coverage on CTI BioPharma in a research note on Thursday, March 31st. They set a “sell” rating for the company.

NASDAQ CTIC opened at $5.32 on Thursday. CTI BioPharma has a one year low of $1.43 and a one year high of $5.76. The stock has a 50-day moving average of $4.71 and a 200 day moving average of $3.26. The company has a market capitalization of $579.70 million, a price-to-earnings ratio of -4.36 and a beta of 0.98.

CTI BioPharma (NASDAQ:CTICGet Rating) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $2.30 million during the quarter, compared to the consensus estimate of $2.15 million. On average, equities research analysts anticipate that CTI BioPharma will post -0.77 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of CTIC. Barclays PLC lifted its holdings in CTI BioPharma by 365.8% in the 3rd quarter. Barclays PLC now owns 26,108 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 20,503 shares in the last quarter. Geode Capital Management LLC lifted its holdings in CTI BioPharma by 11.8% in the 3rd quarter. Geode Capital Management LLC now owns 658,826 shares of the biopharmaceutical company’s stock worth $1,943,000 after purchasing an additional 69,676 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in CTI BioPharma by 4.3% in the 3rd quarter. Stonepine Capital Management LLC now owns 7,964,329 shares of the biopharmaceutical company’s stock worth $23,495,000 after purchasing an additional 331,799 shares in the last quarter. EPIQ Capital Group LLC purchased a new position in CTI BioPharma in the 3rd quarter worth approximately $357,000. Finally, Capstone Investment Advisors LLC purchased a new position in CTI BioPharma in the 3rd quarter worth approximately $149,000. 47.75% of the stock is currently owned by institutional investors.

About CTI BioPharma (Get Rating)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.

See Also

Analyst Recommendations for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.